For example, the dogma in understanding and dealing with ischemic stroke – treating intravenously within a few hours with intravenous tissue plasminogen activator (tPA) to break up the blood clot, in order to minimize the degree of damage – still dominates treatment of this condition. This evidence concerns the gene PLAT and ischemic stroke.